We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+4.62%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$115M
AUM Growth
-$7.74M
Cap. Flow
-$373K
Cap. Flow %
-0.32%
Top 10 Hldgs %
66.12%
Holding
72
New
4
Increased
20
Reduced
11
Closed
4

Top Buys

Rank Stock Value
1
QURE icon
uniQure
QURE
+$963K
2
SLDB icon
Solid Biosciences
SLDB
+$551K
3
KIDS icon
OrthoPediatrics
KIDS
+$494K
4
XENE icon
Xenon Pharmaceuticals
XENE
+$418K
5
PRTA icon
Prothena Corp
PRTA
+$402K

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$1.36M
2
UTHR icon
United Therapeutics
UTHR
+$857K
3
MASI
Masimo
MASI
+$694K
4
AXGN icon
Axogen
AXGN
+$650K
5
CORT icon
Corcept Therapeutics
CORT
+$487K

Sector Composition

Rank Sector Weight
1 Healthcare 96.33%
2 Energy 3.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$124B
$41.8M 36.29%
685,192
+10
+0% +$583
CORT icon
2
Corcept Therapeutics
CORT
$9.72B
$7.54M 6.55%
66,000
-8,000
-11% -$487K
ACAD icon
3
Acadia Pharmaceuticals
ACAD
$4.38B
$4.38M 3.8%
263,400
-75,000
-22% -$1.36M
PRTA icon
4
Prothena Corp
PRTA
$453M
$4.12M 3.58%
332,974
+28,400
+9% +$402K
BDSX icon
5
Biodesix
BDSX
$209M
$3.59M 3.11%
286,806
– –
NBIX icon
6
Neurocrine Biosciences
NBIX
$17.2B
$3.34M 2.9%
30,240
– –
ELUT icon
7
Elutia
ELUT
$42M
$3M 2.61%
1,187,735
-37,754
-3% -$114K
AXGN icon
8
Axogen
AXGN
$2.12B
$2.98M 2.59%
161,000
-36,000
-18% -$650K
PHR icon
9
Phreesia
PHR
$662M
$2.93M 2.55%
114,700
– –
TVTX icon
10
Travere Therapeutics
TVTX
$5.27B
$2.47M 2.15%
138,000
-10,000
-7% -$203K
QDEL icon
11
QuidelOrtho
QDEL
$1.19B
$2.36M 2.05%
67,619
– –
PTGX icon
12
Protagonist Therapeutics
PTGX
$9.06B
$2.32M 2.02%
48,002
+2
+0% +$84
UTHR icon
13
United Therapeutics
UTHR
$22.7B
$2.31M 2.01%
7,500
-2,500
-25% -$857K
DCGO icon
14
DocGo
DCGO
$64.3M
$2.28M 1.98%
864,062
+100,000
+13% +$401K
OVV icon
15
Ovintiv
OVV
$16.2B
$2.23M 1.94%
52,200
– –
HROW icon
16
Harrow
HROW
$1.74B
$1.94M 1.68%
72,910
– –
MASI
17
DELISTED
Masimo
MASI
$1.88M 1.63%
11,280
-4,000
-26% -$694K
EQT icon
18
EQT Corp
EQT
$31B
$1.85M 1.61%
34,619
– –
CSTL icon
19
Castle Biosciences
CSTL
$733M
$1.77M 1.54%
88,404
+10,404
+13% +$258K
ALKS icon
20
Alkermes
ALKS
$8.79B
$1.65M 1.43%
50,000
– –
STOK icon
21
Stoke Therapeutics
STOK
$1.81B
$1.4M 1.21%
210,005
+5
+0% +$47
TMCI icon
22
Treace Medical Concepts
TMCI
$279M
$1.38M 1.2%
164,947
+3,597
+2% +$32.3K
FHTX icon
23
Foghorn Therapeutics
FHTX
$305M
$1.13M 0.99%
310,930
– –
QURE icon
24
uniQure
QURE
$2.77B
$940K 0.82%
88,697
+68,697
+343% +$963K
KALV
25
DELISTED
KalVista Pharmaceuticals
KALV
$773K 0.67%
67,002
+2
+0% +$20
1
2 3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q1 2025 Portfolio in Review

As of Q1 2025, Birchview Capital held 72 positions worth $115M, down 6.3% from $123M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Birchview Capital's Q1 2025 filing shows 4 new, 20 increased, 11 reduced and 4 closed positions. Its largest new stake was Solid Biosciences: 128,768 shares worth $476K. The largest sale was Acadia Pharmaceuticals, an estimated $1.36M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Energy.

  • Birchview Capital's largest Q1 2025 buy was Solid Biosciences: 128,768 shares worth $476K.
  • Birchview Capital added most to uniQure in Q1 2025, an estimated $963K increase.
  • Birchview Capital's biggest Q1 2025 reduction was Acadia Pharmaceuticals, cutting an estimated $1.36M.
  • Birchview Capital fully exited Sarepta Therapeutics in Q1 2025, selling an estimated $426K.
  • Birchview Capital's ten largest holdings make up 66% of its $115M portfolio in Q1 2025.
  • Birchview Capital opened 4 new positions and closed 4 in Q1 2025.
  • Birchview Capital's portfolio value fell 6.3% quarter-over-quarter to $115M.

Based on Birchview Capital's 13F filing for Q1 2025, filed 15 May 2025.